Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC

Author(s):

Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as well as data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%.

Welcome to OncLive On Air^®! I’m your host today, Ashling Wahner.

OncLive On Air is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Regeneron Pharmaceuticals, we had the pleasure of speaking with Edgardo S. Santos, MD, FACP, about 2023 updates from the phase 3 EMPOWER-Lung 1 (NCT03088540) and EMPOWER-Lung 3 (NCT03409614) clinical trials. Dr Santos is an associate professor of clinical biomedical sciences at Florida Atlantic University in Boca Raton, as well as vice chairman of the Florida Society of Clinical Oncology Membership Committee.

In our exclusive interview, Dr Santos discussed key long-term findings from the EMPOWER-Lung 3 trial of cemiplimab-rwlc (Libtayo) plus chemotherapy in patients with advanced non–small cell lung cancer (NSCLC), considerations that arise when evaluating data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%, and how these data emphasize the importance of conducting long-term follow-up analyses in clinical trials.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by Regeneron Pharmaceuticals. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.